这是一项评估安全性、耐受性的开放标签、单中心研究EDG-5506 在 BMD 成人中对肌肉损伤生物标志物和药代动力学 (PK) 的影响。 参加ARCH 研究的 12 名 BMD 成人在研究的前 2 个月最初接受 10 mg 剂量后,在夜间将剂量升级为每日 15 mg 口服剂量的 EDG-5506...
Data from a Phase 1 study calledARCH (NCT05160415) indicated that most men with BMD had stable or improved motor function after a year of treatment with EDG-5506. That’s a notable departure from the typical course of the disease, in which motor function gets steadily worse as time goes o...
The ARCH open label study is evaluating EDG-5506 in 12 adult males with BMD. All those who participated in the Phase 1b first-in-human study of EDG-5506 enrolled in the ARCH study after at least a 3-month washo...
March 4, 2025 · 2 min read · Dan Samorodnitsky Antibody-drug conjugate (ADC) AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win March 4, 2025 · 2 min read · Tristan Manalac Neuropsychiatric disorders ...